[1] |
中华医学会皮肤性病学分会玫瑰痤疮研究中心, 中国医师协会皮肤科医师分会玫瑰痤疮专业委员会. 中国玫瑰痤疮诊疗指南(2021版)[J]. 中华皮肤科杂志, 2021,54(4):279⁃288. doi: 10.35541/cjd.20201078.
|
[2] |
Li J, Wang B, Deng Y, et al. Epidemiological features of rosacea in Changsha, China: a population⁃based, cross⁃sectional study[J]. J Dermatol, 2020,47(5):497⁃502. doi: 10.1111/1346⁃8138. 15301.
|
[3] |
Rainer BM, Kang S, Chien AL. Rosacea: epidemiology, pathogenesis, and treatment[J]. Dermatoendocrinol, 2017,9(1):e1361574. doi: 10.1080/19381980.2017.1361574.
|
[4] |
Stokes JH, Pillsbury DH. The effect on the skin of emotional and nervous states: theoretical and practical consideration of a gastro⁃intestinal mechanism [J]. Arch Derm Syphilol, 1930, 22(6): 962⁃993. doi: 10.1001/archderm.1930.01440180008002.
|
[5] |
Kim M, Choi KH, Hwang SW, et al. Inflammatory bowel disease is associated with an increased risk of inflammatory skin diseases: a population⁃based cross⁃sectional study[J]. J Am Acad Dermatol, 2017,76(1):40⁃48. doi: 10.1016/j.jaad.2016.08. 022.
|
[6] |
Egeberg A, Weinstock LB, Thyssen EP, et al. Rosacea and gastrointestinal disorders: a population⁃based cohort study[J]. Br J Dermatol, 2017,176(1):100⁃106. doi: 10.1111/bjd.14930.
|
[7] |
Jørgensen AR, Egeberg A, Gideonsson R, et al. Rosacea is associated with Helicobacter pylori: a systematic review and meta⁃analysis[J]. J Eur Acad Dermatol Venereol, 2017,31(12):2010⁃2015. doi: 10.1111/jdv.14352.
|
[8] |
Shah A, Morrison M, Burger D, et al. Systematic review with meta⁃analysis: the prevalence of small intestinal bacterial overgrowth in inflammatory bowel disease[J]. Aliment Pharmacol Ther, 2019,49(6):624⁃635. doi: 10.1111/apt.15133.
|
[9] |
Rezaie A, Buresi M, Lembo A, et al. Hydrogen and methane⁃based breath testing in gastrointestinal disorders: the North American Consensus[J]. Am J Gastroenterol, 2017,112(5):775⁃784. doi: 10.1038/ajg.2017.46.
|
[10] |
Bures J, Cyrany J, Kohoutova D, et al. Small intestinal bacterial overgrowth syndrome[J]. World J Gastroenterol, 2010,16(24):2978⁃2990. doi: 10.3748/wjg.v16.i24.2978.
|
[11] |
Grace E, Shaw C, Whelan K, et al. Review article: small intestinal bacterial overgrowth⁃⁃prevalence, clinical features, current and developing diagnostic tests, and treatment[J]. Aliment Pharmacol Ther, 2013,38(7):674⁃688. doi: 10.1111/apt.12456.
|
[12] |
Pimentel M, Saad RJ, Long MD, et al. ACG clinical guideline: small intestinal bacterial overgrowth[J]. Am J Gastroenterol, 2020,115(2):165⁃178. doi: 10.14309/ajg.0000000000000501.
|
[13] |
Salem I, Ramser A, Isham N, et al. The gut microbiome as a major regulator of the gut⁃skin axis[J]. Front Microbiol, 2018,9:1459. doi: 10.3389/fmicb.2018.01459.
|
[14] |
Wang FY, Chi CC. Rosacea, germs, and bowels: a review on gastrointestinal comorbidities and gut⁃skin axis of rosacea[J]. Adv Ther, 2021,38(3):1415⁃1424. doi: 10.1007/s12325⁃021⁃01624⁃x.
|
[15] |
Mahmud MR, Akter S, Tamanna SK, et al. Impact of gut microbiome on skin health: gut⁃skin axis observed through the lenses of therapeutics and skin diseases[J]. Gut Microbes, 2022,14(1):2096995. doi: 10.1080/19490976.2022.2096995.
|
[16] |
O′Neill CA, Monteleone G, McLaughlin JT, et al. The gut⁃skin axis in health and disease: a paradigm with therapeutic implications[J]. Bioessays, 2016,38(11):1167⁃1176. doi: 10. 1002/bies.201600008.
|
[17] |
Gaboriau⁃Routhiau V, Rakotobe S, Lécuyer E, et al. The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses[J]. Immunity, 2009,31(4):677⁃689. doi: 10.1016/j.immuni.2009.08.020.
|
[18] |
Abhishek S, Palamadai Krishnan S. Epidermal differentiation complex: a review on its epigenetic regulation and potential drug targets[J]. Cell J, 2016,18(1):1⁃6. doi: 10.22074/cellj.2016. 3980.
|
[19] |
Maslowski KM, Vieira AT, Ng A, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43[J]. Nature, 2009,461(7268):1282⁃1286. doi: 10.1038/nature08530.
|
[20] |
Szántó M, Dózsa A, Antal D, et al. Targeting the gut⁃skin axis⁃probiotics as new tools for skin disorder management?[J]. Exp Dermatol, 2019,28(11):1210⁃1218. doi: 10.1111/exd.14016.
|
[21] |
Nam JH, Yun Y, Kim HS, et al. Rosacea and its association with enteral microbiota in Korean females[J]. Exp Dermatol, 2018,27(1):37⁃42. doi: 10.1111/exd.13398.
|
[22] |
Chen YJ, Lee WH, Ho HJ, et al. An altered fecal microbial profiling in rosacea patients compared to matched controls[J]. J Formos Med Assoc, 2021,120(1 Pt 1):256⁃264. doi: 10.1016/j.jfma.2020.04.034.
|
[23] |
Parodi A, Paolino S, Greco A, et al. Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its eradication[J]. Clin Gastroenterol Hepatol, 2008,6(7):759⁃764. doi: 10. 1016/j.cgh.2008.02.054.
|
[24] |
Weinstock LB, Steinhoff M. Rosacea and small intestinal bacterial overgrowth: prevalence and response to rifaximin[J]. J Am Acad Dermatol, 2013,68(5):875⁃876. doi: 10.1016/j.jaad. 2012.11.038.
|
[25] |
Gravina A, Federico A, Ruocco E, et al. Helicobacter pylori infection but not small intestinal bacterial overgrowth may play a pathogenic role in rosacea[J]. United European Gastroenterol J, 2015,3(1):17⁃24. doi: 10.1177/2050640614559262.
|
[26] |
Mohammadzadeh R, Mahnert A, Duller S, et al. Archaeal key⁃residents within the human microbiome: characteristics, interactions and involvement in health and disease[J]. Curr Opin Microbiol, 2022,67:102146. doi: 10.1016/j.mib.2022.102146.
|
[27] |
Chibani CM, Mahnert A, Borrel G, et al. A catalogue of 1,167 genomes from the human gut archaeome[J]. Nat Microbiol, 2022,7(1):48⁃61. doi: 10.1038/s41564⁃021⁃01020⁃9.
|
[28] |
Miller TL, Wolin MJ, Conway de Macario E, et al. Isolation of Methanobrevibacter smithii from human feces[J]. Appl Environ Microbiol, 1982,43(1):227⁃232. doi: 10.1128/aem.43.1.227⁃232.1982.
|
[29] |
Hoegenauer C, Hammer HF, Mahnert A, et al. Methanogenic archaea in the human gastrointestinal tract[J]. Nat Rev Gastroenterol Hepatol, 2022,19(12):805⁃813. doi: 10.1038/s41575⁃022⁃00673⁃z.
|
[30] |
Blais Lecours P, Duchaine C, Taillefer M, et al. Immunogenic properties of archaeal species found in bioaerosols[J/OL]. PLoS One, 2011,6(8):e23326. doi: 10.1371/journal.pone.0023326.
|
[31] |
Verma R, Verma AK, Ahuja V, et al. Real⁃time analysis of mucosal flora in patients with inflammatory bowel disease in India[J]. J Clin Microbiol, 2010,48(11):4279⁃4282. doi: 10. 1128/JCM.01360⁃10.
|
[32] |
Yamabe K, Maeda H, Kokeguchi S, et al. Distribution of archaea in Japanese patients with periodontitis and humoral immune response to the components[J]. FEMS Microbiol Lett, 2008,287(1):69⁃75. doi: 10.1111/j.1574⁃6968.2008.01304.x.
|
[33] |
Samuel BS, Hansen EE, Manchester JK, et al. Genomic and metabolic adaptations of Methanobrevibacter smithii to the human gut[J]. Proc Natl Acad Sci U S A, 2007,104(25):10643⁃10648. doi: 10.1073/pnas.0704189104.
|
[34] |
Bang C, Weidenbach K, Gutsmann T, et al. The intestinal archaea Methanosphaera stadtmanae and Methanobrevibacter smithii activate human dendritic cells[J/OL]. PLoS One, 2014,9(6):e99411. doi: 10.1371/journal.pone.0099411.
|
[35] |
Jun YK, Yu DA, Han YM, et al. The relationship between rosacea and inflammatory bowel disease: a systematic review and meta⁃analysis[J]. Dermatol Ther (Heidelb), 2023,13(7):1465⁃1475. doi: 10.1007/s13555⁃023⁃00964⁃6.
|
[36] |
Wu YB, Li XJ, Chen SY, et al. Inflammatory bowel disease and rosacea: a two⁃sample mendelian randomization study[J]. Dermatologic Therapy, 2023. doi: 10.1155/2023/1353823.
|